Share on LinkedInShare on LinkedIn

ARTICLE · 08 AUGUST 2023

PMPRB Updating Interim Guidance

Gowling WLG
Gowling WLG
Contributor
Gowling WLG

Gowling WLG

The firm The firm’s lawyers speak English, French, Russian and Ukrainian. The firm’s client base...

View firm profile
Explore more from Gowling WLG

On June 20, 2023 the Patented Medicine Prices Review Board (PMPRB) invited stakeholders to comment on its proposed amendment for conducting interim price reviews on New Medicines...

CanadaIntellectual Property

On June 20, 2023 the Patented Medicine Prices Review Board (PMPRB) invited stakeholders to comment on its proposed amendment for conducting interim price reviews on New Medicines per the Interim Guidance. The Interim Guidance, introduced by the PMPRB on August 18, 2022, refers to the interim period approach for reviewing the prices of patented medicines. Part of the Interim Guidance established a process where existing medicines are reviewed based on the relevant Non-Excessive Average Price (NEAP) projected in the 2021 compliance letters sent to applicable patentees by the PMPRB in March 2022.

However, the Interim Guidance also established that New Medicines, medicines without a projected a Maximum Average Potential Price (MAPP) or NEAP as of July 1, 2022, would not be subject to PMPRB price reviews during this interim period.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from